Riad Mishlawi to become CEO of Hikma Pharma

Published On 2023-04-13 06:45 GMT   |   Update On 2023-04-13 06:46 GMT
Advertisement

New Delhi: Generic drugmaker Hikma Pharmaceuticals Plc said on Wednesday that Riad Mishlawi, president of the group's injectables business, will become its chief executive officer, effective Sept. 1.

The London-based company said once Mishlawi takes up the role, Said Darwazah will step down as acting CEO and return to his role as executive chairman.
Mishlawi, who has been with Hikma for more than 26 years over two separate stints, was instrumental in the growth and global expansion of the group's injectables business into a market-leading position.
Advertisement
The FTSE midcap firm said Mishlawi will join the board and relocate from Portugal to the company's U.S. headquarters in Berkeley Heights, New Jersey.
He replaces Sigurdur Olafsson, who stepped down in June last year after four years at the London-listed drugmaker, weeks after the company cut its annual sales and margin forecasts for its generics unit

Read also: Hikma Pharma unveils authorized generic of Xyrem in US







Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News